As Novo Nordisk and Eli Lilly struggle to keep up with soaring demand for their popular diabetes and weight loss drugs, healthcare companies are introducing supply trackers to help patients navigate ongoing shortages.
New research shows that tirzepatide, the latest FDA-approved obesity drug, really can help people lose substantial amounts of weight—but only if they continue taking it. The study found that people who stopped taking tirzepatide after 36 weeks regained much of their lost weight within a year, while those who continued…
